Abstract
Background
This survey sought to determine Japanese gynecologists’ attitudes concerning administering hormone replacement therapy (HRT) for patients after surgery for endometrial cancer (EC).
Methods
Eight hundred and eighty-eight members of the Japanese Gynecologic Oncology Group (JGOG) were asked to respond to an anonymous questionnaire on the JGOG website. The survey asked whether or not HRT was to be administered when surgery was performed (including a hysterectomy and bilateral oophorectomy) to treat EC before or after menopause. If HRT was not to be administered, respondents were asked the reason why. Respondents were presented with the same hypothetical patients that were featured in a previous survey in Germany, and differences in the mindsets of Japanese and German physicians were compared.
Results
Responses from 363 individuals (response rate 40.9 %) were analyzed. Seventy-eight percent of physicians considered HRT for patients undergoing surgery before menopause. The most prevalent reason of refusal to prescribe HRT was the risk of EC recurrence. Forty-eight percent of physicians considered HRT for patients undergoing surgery after menopause. The most prevalent reasons of refusal of HRT were its limited benefit and the availability of alternative therapies. Sixty-five percent of Japanese physicians responded that they would administer HRT to patients with low risk of recurrence vs. 46 % of physicians in Germany (P < 0.0002). Forty-nine percent of Japanese physicians approved of prescribing HRT for patients with high risk of recurrence vs. 25 % of physicians in Germany (P < 0.0001).
Conclusion
Many Japanese gynecologists have a favorable attitude toward prescribing HRT after treatment of EC.
Similar content being viewed by others
References
Amant F, Moerman P, Neven P et al (2005) Endometrial cancer. Lancet 366(9484):491–505
Aoki D (2014) Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013. J Obstet Gynaecol Res 40(2):338–348
Decruze SB, Green JA (2007) Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 17(5):964–978
Kilic S, Yilmaz N, Erdogan G et al (2010) Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. Climacteric 13(1):55–62
Creasman WT, Henderson D, Hinshaw W et al (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67(3):326–330
Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36(2):189–191
Chapman JA, DiSaia PJ, Osann K et al (1996) Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175(5):1195–1200
Suriano KA, McHale M, McLaren CE et al (2001) Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 97(4):555–560
Ayhan A, Taskiran C, Simsek S et al (2006) Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 16(2):805–808
Barakat RR, Bundy BN, Spirtos NM et al (2006) Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 24(4):587–592
Hancke K, Foeldi M, Zahradnik HP et al (2010) Estrogen replacement therapy after endometrial cancer: a survey of physicians’ prescribing practice. Climacteric 13(3):271–277
Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists (2001) ACOG committee opinion: tamoxifen and endometrial cancer. Int J Gynecol Obstet 73(1):77–79
Querleu D, Planchamp F, Narducci F, Institut National du Cancer; Societe Francaise d’Oncologie Gynecologique et al (2011) Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d’Oncologie Gynécologique. Int J Gynecol Cancer 21(5):945–950
Japan Society of Gynecologic Oncology (2013) Endometrial cancer treatment guidelines. Kanehara & CO., LTD
Rossouw JE, Anderson GL, Prentice RL, Writing Group for the Women’s Health Initiative Investigators et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333
Holinka CF, Hata H, Gravanis A et al (1986) Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa line). J Steroid Biochem 25(58):781–786
Farnell YZ, Ing NH (2003) The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 84(4):453–461
Rozenberg S, Vasquez JB (2000) Estrogen replacement therapy in patients with endometrial cancer: prescription attitude of Belgian gynecologists. Maturitas 35(2):125–128
Vavilis D, Tsolakidis D, Goulis DG et al (2011) Hormone therapy for postmenopausal endometrial cancer survivors: a survey among Greek obstetricians-gynaecologists. Eur J Gynaecol Oncol 32(1):81–83
Lee SJ, Yeo SG, Kang SB et al (2013) Attitudes and practices of Korean gynecologists towards hormone replacement therapy in endometrial cancer survivors. Eur J Gynaecol Oncol 34(6):513–517
Rocca WA, Grossardt BR, de Andrade M et al (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7(10):821–828
Yoshida T, Takahashi K, Yamatani H et al (2011) Impact of surgical menopause on lipid and bone metabolism. Climacteric 14(4):445–452
Atsma F, Bartelink ML, Grobbee DE et al (2006) Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13(2):265–279
Acknowledgments
We thank all members who participated in this JGOG survey. We also thank Mr. Shigeru Honda and Ms. Aya Noguchi of the JGOG secretariat for their kind assistance.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Consortia
Corresponding author
About this article
Cite this article
Yokoyama, Y., Ito, K., Takamatsu, K. et al. How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey. Int J Clin Oncol 20, 997–1004 (2015). https://doi.org/10.1007/s10147-015-0808-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-015-0808-5